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Stroke is the second leading cause of death and the main cause of long-term disability
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in the world. Therefore, treatment of the sequelae of stroke is one of the most
important challenges in clinical neurotherapy. A 63-year-old Chinese woman with
inarticulateness and right limb physical activity disorder for more than 4 months
received olfactory ensheathing cells (OECs)-based neurorestorative therapy during
the stay in hospital. Her neurological functions improved during 1-year follow-up.
This case report showed that OECs therapy could be a treatment option for cerebral
infarction sequela.
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1

Background

Stroke is the second leading cause of death and the
main cause of long-term disability with 6.24 million
death cases every year in the world [1]. Currently, there
are only two FDA-approved treatments for ischemic
stroke: tissue plasminogen activator intravenous
thrombolysis and stent-assisted thrombectomy [2].
However, they can only be used in patients with
hyperacute ischemic stroke, thus only a relatively small
group of patients have chances to receive timely and
effective treatments. Besides, stroke has a mortality
of more than a quarter and a poor prognosis with a
permanent disability of 40% [1]. Treatments, nursing
and long-term rehabilitation impose heavy burdens
on patients and their families.
In recent years, cell transplantations have been
showed of great therapeutic potential in neurorestoration. A number of studies have demonstrated
Corresponding author: Xiaoling Guo, E-mail: gxl266@sina.com

that olfactory ensheathing cells (OECs) function in
secretory [3, 4], tissue remodeling [5], tissue migration
[6–8] and immune regulation [8, 9], and are prominent
in repairing various nervous system diseases. In
particular, OECs have eminent ability to stimulate
axonal repair, enhance plasticity and support axonal
retention in the central nervous system (CNS) [10].
OECs could be one of the potential candidates of cell
transplant strategies to repair CNS diseases [11]. The
following case report of OECs nasal submucosal
transplantation improving cerebral infarction sequelae
in our hospital will provide a novel therapeutic
option for patient with similar conditions.

2
2.1

Case report
General information

The 63 years old female patient, who was admitted to
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our hospital because of “inarticulateness and right limb
physical activity disorder for more than 4 months”,
was suddenly found to have inarticulateness, unclear
pronunciation, incomprehensible expression and the
right limb physical activity disorder 4 months ago,
and was diagnosed as “acute cerebral infarction” and
“hypertension level 3 (very high added risk)” by
local hospital in January 2017.
After arterial thrombectomy, anti-platelet aggregation
and rehabilitation treatments, the clinical symptoms
were improved. Unfortunately, the right upper extremity
of the patient could only be lifted slightly with an
incapacitated right hand. The patient could only walk
on crutches due to right lower extremity muscle
weakness, and inarticulateness and expression disorder
symptoms still existed.
The patient had a history of hypertension for three
years and the systolic blood pressure could reach
220 mmHg, but the blood pressure was basically well
controlled through long-term regular medication.
Clinical examinations showed that the patient was
conscious, ataxic aphasia, right central facial-lingual
paralysis, right side of the body hypoalgesia. The right
upper limb proximal muscle strength was level 3,
distal muscle strength was level 0, right lower limb
muscle strength was level 4‒. The muscle tension was
slightly higher, the right limb tendon reflex was (+++),
the left limb tendon reflex was (++), and right bilateral
Babinski sign was positive.
The magnetic resonance imaging (MRI) of brain
(01/04/2017) showed patchy long T1 and long T2 signal
in the left frontal white matter, left basal ganglia and
left temporal-occipital-parietal junction. The magnetic
resonance angiography (MRA) (01/04/2017) showed
the vessel walls in intracranial segment of bilateral
internal carotid artery, bilateral middle cerebral artery
and anterior cerebral artery were rough. The M2
segment (insula segment)of the left middle cerebral
artery was slender (Fig. 1). The admission diagnoses
were “hypertension grade 3 (very high added risk)
and sequelae of cerebral infarction”.
2.2
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Fig. 1

MRI and MRA. (A) and (B) are the patient's MRI images

(A, T1; B, T2) (1 month before OECs treatment). (C) is the patient's
MRA image.

Professional Committee of Chinese Medical Doctor
Association and Research Ethics Committee of 981
Hospital of the Joint Logistics Support Force of the
Chinese People’s Liberation Army (the 266 Hospital
of PLA).
2.3 Interventions, transplanted cell acquisition
and preparation
OECs were obtained from donated aborted embryo
(3 to 4 months, pregnant women and their family
members have signed informed consent) from cooperative hospitals, and were prepared and identified in
accordance with literature [12] (Fig. 2).
2.4 Cell transplantation
After admission, antiplatelet aggregation, statins and
other drugs were given symptomatically, and subsequently rehabilitation treatments were used. At
07/05/2018, 5 × 106 (0.3 mL)/side of OECs were injected
into bilateral nasal olfactory submucosa (Fig. 3).
2.5

Follow-up

The patient was follow-up by assessment of muscle
strength measurement, National Institute of Health

Ethic

The patient was fully informed and signed the informed
consent for the treatment. The clinical research program
and agreement were approved by Neurorestoratology

Fig. 2 OECs are showed in red (P75+, 100×).
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MRI at 20/04/2018 showed patchy long T1 and long T2
signal in left basal ganglia and left temporal-occipital
junction (Fig. 4).

4

Fig. 3

In recent decades, due to the rapid development of
science and technology, ultra-early imaging diagnosis
is guiding the active treatments of ischemic stroke and
the subsequent secondary preventions are gradually
standardized, so that the mortality caused by
cerebrovascular disease is gradually reduced. However,
stroke remains the leading cause of death and longterm disability worldwide [13]. The occurrence of
stroke is accompanied by many pathophysiological
processes such as inflammation, endothelial dysfunction, thrombosis and oxidative stress. The known risk
factors cannot fully explain the accurate pathological
mechanism of stroke, nor they can fully explain the
adverse prognosis of stroke [14]. Generally, 80% stroke
cases are ischemic stroke [15]. Ischemic events trigger
complex molecular cascade reactions, including cell
depolarization, excitotoxicity, impaired cellular energy
metabolism, and disruption of the blood-brainbarrier [3]. Current treatments of ischemic stroke are
limited to restore perfusion, promote circulation
and protect cells from acute death [16]. Therefore,
functional neurological recovery in the subacute and
chronic phases of ischemic stroke remains one of the
most challenging tasks in clinical neurorestorative
practice [17].

Nasal olfactory submucosal injection of OECs.

Stroke Scale (NIHSS), the Modified Rankin Score,
Barthel Index Score and modified Ashworth Score at
before treatment, and 1 month, 3 months, 6 months,
1 year after treatment. And MRI were done 1 year
after treatment.

3

Discussion

Results

Before treatment, the patient had inarticulateness,
unclear pronunciation and incomprehensible expression.
1 month after treatment, although the patient still had
inarticulateness, her pronunciation was improved and
others could understand the semantics. 3 and 6 months
after treatment, the patient was not fluent in speech,
spoke slowly and communicated with others normally.
One year after treatment, the patient was basically
fluent in speech, spoke slowly and communicated with
others normally. Specific muscle strength and various
neurological function scores were shown in Table 1
and Table 2. After one year, the NIHSS score was 5
(face 2, speech 1, movement 1, feeling 1). The reviewed

Table 1 The results of muscle strength measurement.
Muscle strength (level)

Before
treatment

1 month after
treatment

3 months after
treatment

6 months after
treatment

1 year after
treatment

Proxima of right upper limb

3

3

3+

4‒

4+

Distal of right upper limb

0

0

2

2

3

Right lower limb

4‒

4

4

4+

4+

Table 2 The results of NIHSS, Modified Rankin Score, Barthel Index Score and Modified Ashworth Score.
Before
treatment

1 month after
treatment

3 months after
treatment

6 months after
treatment

1 year after
treatment

NIHSS (score)

10

10

9

7

7

Modified Rankin Score (score)

4

3

3

2

2

Barthel Index Score (score)

60

60

70

85

90

Modified Ashworth Score (level)

1

1

1

1

1
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Fig. 4 The images of MRI 1 year after OECs treatment. (A) T1;
(B) T2.

OECs, special glial cells originated in the nasal
mucosa, are distributed in the first, second and olfactory
nerves of the olfactory bulb, envelop the olfactory nerve
bundle into the olfactory bulb, wrap the olfactory
nerves and enter into brain with the olfactory axons.
OECs help to separate olfactory axons from other cells
in brain. OECs can induce the olfactory nerve to enter
the central nerve system. Therefore, the olfactory nerve
has excellent regenerative ability and could renew
consecutively. The regenerated axons could grow
through the border between peripheral and central
nerve system, build synaptic connections with the
olfactory bulb. This process is repeated once every
1 to 2 months. This particular glial cell is an external
condition and plays an important role in central
nerve system regeneration [18, 19]. Many molecules
(NCAM, L1, N-cadherin) [20] related to cell adhesion
and axon growth are expressed on OECs membrane,
support and promote the growth and survival of
neurons, improve the microenvironment in damaged
CNS tissues, activate resting axons and neurons, restore
nerve conduction, promote axonal regeneration and
myelination repair, and restore some of the lost nerve
function [21]. OECs also secrete soluble factors that
promote neural differentiation and neurite elongation.
Secreted matrix metalloproteinase 2 (MMP2), sonic
hedgehog protein (Shh), laminin and fibronectin
could induce neural progenitor cells to differentiate
into neurons, regulate neural cells migration and
differentiation in different tissues in the body. OECs
direct olfactory axons from the nasal olfactory mucosa
to the olfactory bulb, connect the peripheral nervous
system (PNS) and the CNS, support the continuous
renewal of olfactory neurons in the olfactory system
and stimulate axonal repair and functional recovery
[22]. Due to the strong axonal outgrowth guiding

85

ability of OECs, increasing evidence showed that
OECs have therapeutic potential in neurorestorative
therapy [23]. Studies have confirmed that OECs have
neurorestorative properties in animal stroke model.
Transplanted OECs have been reported to survive for
over 8 weeks and could migrate to infarcted tissue
and long distances along the white matter. It can
increase white matter markers, reduce lesion volume
and improve neurological score [16]. Human OECs
have been observed to significantly improve neural
function and promote neuroplasticity in the ischemic
brain of rats and mice [17].
In recent years, cell therapy has been proven to be
a promising clinical treatment option for CNS diseases
or injuries [24]. OECs transplantation has become a
hotspot in the field of Neuroresotratology. It is one of
the most potential therapeutic methods of CNS diseases.
Its clinical applications have been carried out in many
medical research centers [25–28]. In this case, although
the patient received timely arterial thrombectomy
after the onset of stroke, the neurological impairment
remained. The dysfunction did not improve in the
following 4 months after stroke.
After 1 year’s follow-up, the language function
improved 1 month after treatment, while did not
improve in the golden recovery period of 3 months
after stroke. The muscle strength of the right lower
limb improved one month after treatment and the
muscle strength of the right upper limb improved
significantly 3 months after treatment. Specially, the
muscle strength of distal right upper limb recovered
from level 0 to 2 in the third month and reached 4 at
1 year after treatment. The NIHSS score decreased
from 10 to 7 before treatment. Modified Rankin Score
decreased from 4 to 2. The Barthel Index Score
increased from 60 to 90, daily life was basically on its
own, which greatly reduced the burden of the family
economy and nursing. Although muscle tension was
improved, there was no significant change in the
Modified Ashworth Score, which may be related to the
less degree of dystonia itself. This is the first clinical
case report of OECs-based neurorestorative therapy
treating a cerebral infarction sequela patient by nasal
olfactory submucosal transplantation, which shows
some promising results.
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Conclusion

The treatment results in this case suggest that OECs
transplantation may be a selective or alternative
therapy to improve the sequelae of stroke. However
Multi-center larger sample clinical trials are still needed.
The combination of multiple cell and multiple pathway
intervention strategies may have great potential to
improve or restore neurological functions in CNS
diseases and damage in the future.
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